FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:171-178 July 8, 2004 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Presentation of Case

A 63-year-old man was evaluated in the clinic because of metastatic prostate cancer that was no longer responding to hormone therapy.

The patient had been well until eight years before he came to the clinic, when he had noticed a decreased urinary stream and urinary hesitancy. A test for prostate-specific antigen (PSA) six months later showed a level of 2.7 ng per milliliter; six months after that, the PSA level was 7.7 ng per milliliter. A transrectal needle biopsy of the prostate showed adenocarcinoma, Gleason grade 3 to 4 (on a scale of 1 to 5, with 1 indicating low-grade . . . [Full Text of this Article]

Discussion of Management

Management of Localized Prostate Cancer

            Radical Prostatectomy

            Radiation Therapy

Management of Locally Advanced Prostate Cancer

            Radiation Therapy

            Hormonal Therapy

            Chemotherapy

Anatomical Diagnosis

Source Information

From the Division of Medical Oncology, Department of Medicine (D.S.K.), and the Departments of Urology (W.S.M.), Radiation Oncology (A.L.Z.), Radiology (M.G.H.), and Pathology (R.H.Y.), Massachusetts General Hospital; and the Departments of Medicine (D.S.K.), Urology (W.S.M.), Radiation Oncology (A.L.Z.), Radiology (M.G.H.), and Pathology (R.H.Y.), Harvard Medical School.

This article has been cited by other articles:

• (2004). Management of localised prostate cancer. DTB 42: 81-85 [Abstract] [Full Text]